Literature DB >> 21507205

Discovery of potential integrin VLA-4 antagonists using pharmacophore modeling, virtual screening and molecular docking studies.

Sundarapandian Thangapandian1, Shalini John, Sugunadevi Sakkiah, Keun Woo Lee.   

Abstract

Very late antigen-4 (VLA-4) is an integrin protein, and its antagonists are useful as anti-inflammatory drugs. The aim of this study is to discover novel virtual lead compounds to use them in designing potent VLA-4 antagonists. A best pharmacophore model was generated with correlation coefficient of 0.935, large cost difference of 114.078, comprising two hydrogen bond acceptors and three hydrophobic features. It was further validated and used in database screening for potential VLA-4 antagonists. A homology model of VLA-4 was built and employed in molecular docking of screened hit compounds. Finally, two compounds were identified as potential virtual leads to be deployed in the designing of novel potent VLA-4 antagonists.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21507205     DOI: 10.1111/j.1747-0285.2011.01127.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  4 in total

1.  An integrated QSAR modeling approach to explore the structure-property and selectivity relationships of N-benzoyl-L-biphenylalanines as integrin antagonists.

Authors:  Sk Abdul Amin; Nilanjan Adhikari; Sonam Bhargava; Shovanlal Gayen; Tarun Jha
Journal:  Mol Divers       Date:  2017-11-17       Impact factor: 2.943

2.  Dehydro-β-proline Containing α4β1 Integrin Antagonists: Stereochemical Recognition in Ligand-Receptor Interplay.

Authors:  Alessandra Tolomelli; Monica Baiula; Angelo Viola; Lucia Ferrazzano; Luca Gentilucci; Samantha Deianira Dattoli; Santi Spampinato; Eusebio Juaristi; Margarita Escudero
Journal:  ACS Med Chem Lett       Date:  2015-05-05       Impact factor: 4.345

3.  Exploration of structural and physicochemical requirements and search of virtual hits for aminopeptidase N inhibitors.

Authors:  Amit K Halder; Achintya Saha; Tarun Jha
Journal:  Mol Divers       Date:  2013-01-23       Impact factor: 2.943

4.  Development of a human dihydroorotate dehydrogenase (hDHODH) pharma-similarity index approach with scaffold-hopping strategy for the design of novel potential inhibitors.

Authors:  Kuei-Chung Shih; Chi-Ching Lee; Chi-Neu Tsai; Yu-Shan Lin; Chuan-Yi Tang
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.